NWBO — Northwest Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $258.75m
- $320.52m
- $1.38m
Brief: Northwest Biotherapeutics extends exercise period of series B warrants
Brief: Northwest Biotherapeuticsannounces operations updates
Woodford trust changes strategy, drops capital raising (updated)
Brief: Northwest biotherapeutics files for non-timely 10-k - sec filing
Brief: Northwest Biotherapeutics says registered direct offering of up to $27.6 mln with existing institutional investors
Brief: NW Bio issues statement on adverse market conditions and NW bio stock decline
Brief: Northwest Biotherapeutics says registered direct offering of $12.6 mln
Brief: NW Bio says not a fit for Elliott Leary to join board
Brief: Northwest Biotherapeutics Inc announces establishment of special committee and law firm to conduct independent investigation of recent allegations
Brief: NW Bio says board is committed to adding an additional independent director
Brief: Northwest Biotherapeutics files for mixed shelf offering - SEC filing
Brief: NW Bio enters into agreement with Woodford for $30 mln of equity funding
Brief: Northwest Biotherapeutics issues statement on highly unusual trading activity
Brief: Woodford Investment Management reports 26.2% stake in Northwest Biotherapeutics as of June 9, 2015
Brief: Nw bio confirms phase III trial of DCVax-L for GBM brain cancer is ongoing
Northwest Bio suspends patient screening in brain cancer trial
Northwest Bio suspends screening of patients in brain cancer trial
Brief: NW Bio announces $40 million financing
Brief: Northwest Biotherapeutics announces financings totaling $35 million